Jump Financial LLC Invests $1.67 Million in Ascendis Pharma A/S (NASDAQ:ASND)

Jump Financial LLC acquired a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 12,105 shares of the biotechnology company's stock, valued at approximately $1,666,000.

Other large investors also recently bought and sold shares of the company. Guggenheim Capital LLC lifted its position in shares of Ascendis Pharma A/S by 256.9% during the fourth quarter. Guggenheim Capital LLC now owns 7,249 shares of the biotechnology company's stock valued at $998,000 after buying an additional 5,218 shares during the last quarter. Mariner LLC raised its stake in shares of Ascendis Pharma A/S by 31.0% during the 4th quarter. Mariner LLC now owns 2,160 shares of the biotechnology company's stock worth $297,000 after acquiring an additional 511 shares in the last quarter. Sterling Capital Management LLC boosted its stake in Ascendis Pharma A/S by 19.0% in the fourth quarter. Sterling Capital Management LLC now owns 56,850 shares of the biotechnology company's stock valued at $7,827,000 after acquiring an additional 9,065 shares in the last quarter. FIL Ltd grew its holdings in Ascendis Pharma A/S by 13.9% in the fourth quarter. FIL Ltd now owns 729,275 shares of the biotechnology company's stock worth $100,399,000 after purchasing an additional 89,016 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in Ascendis Pharma A/S by 1,577.6% in the fourth quarter. Legal & General Group Plc now owns 17,682 shares of the biotechnology company's stock worth $2,433,000 after purchasing an additional 16,628 shares during the last quarter.

Ascendis Pharma A/S Price Performance

ASND opened at $165.05 on Friday. The firm has a fifty day moving average price of $152.00 and a 200 day moving average price of $138.14. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $169.37. The stock has a market cap of $10.06 billion, a P/E ratio of -23.25 and a beta of 0.54.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, topping analysts' consensus estimates of ($1.32) by $0.64. Equities analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Analysts Set New Price Targets

ASND has been the topic of several research analyst reports. UBS Group began coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They set a "buy" rating and a $196.00 target price on the stock. Morgan Stanley set a $180.00 price objective on shares of Ascendis Pharma A/S in a research report on Tuesday, February 18th. Evercore ISI boosted their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 18th. Royal Bank of Canada began coverage on shares of Ascendis Pharma A/S in a report on Wednesday. They issued an "outperform" rating and a $205.00 price target for the company. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an "overweight" rating in a report on Tuesday, March 18th. Two equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $204.67.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.